Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04048018 · ClinicalTrials.gov registry record
Performance Evaluation of the VIDAS TB-IGRA Assay.
A clinical trial, sponsored by BioMérieux.
- Completed
- Registry status
- 2,401
- Enrollment target
NCT04048018 is a clinical trial that has completed, run by BioMérieux. The registered enrollment target is 2,401 participants.
The verdict
NCT04048018 has completed, sponsored by BioMérieux.
- COMPLETED
- Registry status
- 2,401 participants
- Enrollment target
Study Summary
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.
Interventions
- DIAGNOSTIC_TEST Blood draw and IGRA test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,401 participants |
| Start Date | 2019-12-05 |
| Est. Completion | 2021-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04048018
The ClinicalTrials.gov registry entry for NCT04048018 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,401 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMérieux, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood draw and IGRA test is the first listed.
NCT04048018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04048018 about?
NCT04048018 is a clinical study titled "Performance Evaluation of the VIDAS TB-IGRA Assay.". This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diag...
What is the current status of trial NCT04048018?
This trial is currently completed. The enrollment target is 2,401 participants. The study started on 2019-12-05. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT04048018?
The interventions under investigation include: Blood draw and IGRA test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04048018?
This trial is sponsored by BioMérieux, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.